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Abstract
Background—This trial tested the effects of multidisciplinary group clinic appointments on the 
primary outcome of time to first HF rehospitalization or death.
Methods and Results—HF patients (N=198) were randomly assigned to standard care or 
standard care plus multidisciplinary group clinics. The group intervention consisted of 4 weekly 
clinic appointments and one booster clinic at month 6, where multidisciplinary professionals 
engaged patients in HF self-management skills. Data were collected prospectively for 12 months 
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beginning after completion of the first four group clinic appointments (2 months post 
randomization). The intervention was associated with greater adherence to recommended 
vasodilators (p=0.04). The primary outcome (first HF-related hospitalization or death) was 
experienced by 22 (24%) in the intervention group and 30 (28%) in standard care. The total HF-
related hospitalizations, including repeat hospitalizations after the first time; were 28 in the 
intervention group and 45 among those receiving standard care. The effects of treatment on 
rehospitalization varied significantly over time. From 2-7 months post randomization, there was a 
significantly longer hospitalization-free time in the intervention group (Cox proportional HR = 
0.45 (95% CI = 0.21, 0.98; p=0.04). No significant difference between groups was found from 
month 8 through 12 (HR = 1.7, 95% CI = 0.7, 4.1).
Conclusions—Multidisciplinary group clinic appointments were associated with greater 
adherence to selected heart failure medications and longer hospitalization-free survival during the 
time that the intervention was underway. Larger studies will be needed to confirm the benefits 
seen in this trial and identify methods to sustain these benefits.
Keywords
heart failure; group clinic; clinical trial; rehospitalization; survival analysis
Heart Failure (HF) affects approximately 5 million Americans and is expected to have a 
23% increase in prevalence by 2030. [1] HF is the most frequent cause for hospitalization 
among Medicare beneficiaries. Accordingly, Medicare has adopted new reimbursement 
policies with penalties to hospitals for higher readmission rates after a HF discharge. [2] 
This has created a pressing need to develop better strategies for minimizing 
rehospitalizations. Indeed, current guidelines emphasize the importance of implementing 
systems to coordinate and deliver effective care.[3] Yet, recent meta-analyses and clinical 
management reviews have found most HF interventions are resource intensive, difficult to 
replicate and don’t improve the high rate of repeat hospitalizations.[4,5]
One strategy that still holds promise for reducing HF readmissions is to improve patients’ 
abilities to self-manage their disease. This requires that HF patients learn how to use specific 
HF home-care skills and implement complex daily self-care tasks.[6] Notably, patients are 
often discharged from the hospital with unresolved HF symptoms and with few HF self-
management skills.[7] In fact, many HF patients lack the basic knowledge needed for 
appropriate dietary management,[8] are unsure of basic weight and fluid self-monitoring 
practices, and delay seeking treatment for HF symptoms, all of which can result in frequent 
rehospitalizations.[9]
Group clinic appointments, also known as ‘shared medical appointments’ have the potential 
to address these challenges and improve care for HF patients.[10] Group clinic appointments 
can provide more extensive education than is usually offered in traditional office visits, can 
provide more face time with healthcare providers and, perhaps most importantly, can give 
patients the opportunity to identify self-management issues and engage in shared problem 
solving with multidisciplinary professionals and fellow patients.[11] For patients with 
diabetes and other chronic illnesses, group clinic appointments have been associated with 
better treatment adherence.[12] However, the impact of group clinic appointments on HF 
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clinical outcomes has rarely been studied in controlled trials.[5] Two small pilot studies 
suggested that HF group appointments could improve HF knowledge, decrease HF 
rehospitalizations, and promote greater satisfaction with treatment.[13,14]
To examine the impact of an efficient, standardized group clinic program in HF, we 
developed the Self-Management and Care of Heart Failure (SMAC-HF) program and 
prospectively tested its impact on HF related rehospitalizations in a randomized controlled 
trial.
Methods
Between March 2007 and April 2011, we enrolled patients hospitalized for an exacerbation 
of HF into a randomized controlled clinical trial of multidisciplinary group clinic 
appointments. After giving written informed consent, patients were randomized to receive 
either standard care or the SMAC-HF group appointment intervention. Patients were 
prospectively followed for 12 months after randomization. The study was reviewed and 
approved by the Institutional Review Board (IRB) of the University of Kansas Medical 
Center. In addition, the study progress was reviewed and approved annually by an external 
Data Safety and Monitoring Board comprised of a cardiologist, a statistician, and an IRB 
representative.
Subjects
Hospitalized HF patients were prospectively identified by reviewing the daily admission 
records of all patients at a single academic medical center. Eligible patients had to have been 
hospitalized with NYHA class III or IV HF, but were not required to have a reduced left 
ventricular ejection fraction (EF). Exclusion criteria were evidence of transient, reversible 
HF, a planned heart transplant, end-stage renal disease (creatinine > 4 mg/dl), unresected 
malignancy or other terminal illness, or discharge to a nursing home, rehabilitation unit, or 
extended care facility. Patients were also excluded if they had a condition that would 
preclude them from engaging in the group clinic intervention, including blindness, deafness, 
dementia, cognitive deficiency or could not write and speak in English.
Nurses who were trained on trial enrollment procedures, informed consent and baseline data 
collection then enrolled patients during or within 2 weeks of their index hospitalization. Of 
the 774 patients identified with HF and meeting the criteria for enrollment, 198 (26%) were 
enrolled in the study (Figure 1). The primary reasons for patients not enrolling in the study 
were either those patients were “not interested” or that study staff failed to reach the patient 
within 2 weeks of discharge.
Randomization
In order to form groups of patients for the clinic appointments in a timely fashion, blocks of 
patients were randomized rather than individual patients. Block sizes ranged from 4 to 8 
participants. Depending on the rate of subject recruitment, it typically took up to 3 weeks to 
form a group, randomize the group, and initiate the group visits. The initial group clinic 
schedule was a series of 4 weekly appointments, thus the intervention clinics typically did 
not finish until 8 weeks post randomization. Thus, randomization plus 8 weeks (month 2) 
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was the time pre-specified to begin observation for HF related endpoints. The same 
observation period was pre-specified for both comparison groups.
After 4 to 8 participants had consented, that whole block of patients was randomly assigned 
to receive either the intervention or standard care. Randomization was blinded so that no 
patient or project staff was aware of the allocation until after that block of patients was 
randomized. We enrolled 32 blocks containing a total of 198 study subjects, of whom 106 
(53%) were in blocks that were randomized to standard care and 92 (47%) were in blocks 
randomized to receive the SMAC-HF intervention.
Standard Care and Intervention Descriptions
Standard care—Patients in both treatment arms received HF care from their existing 
treatment team both during and after hospitalization. This care typically included education 
from a discharge nurse that addressed the national HF core measures requirements, a post-
discharge phone call from a NP within 3-7 days after discharge, and a follow-up at 
outpatient MD clinic visit within one month of discharge, with many patients seen sooner 
depending on their clinical status. Patients’ HF related medications were initiated or up-
titrated per their provider based on clinical need. There were no differences in the 
percentage of patients seen by NP under the direction of a cardiologist versus an MD only 
between subjects in the intervention and control group (χ2= 1.25, p=.32).
SMAC-HF intervention—The SMAC-HF intervention began with four weekly group 
visit appointments followed by a 5th ‘booster’ appointment held 6 months after 
randomization. The first series of 4 weekly group clinic appointments were completed 
within 8 weeks after randomization. Transportation vouchers were provided for travel to 
each group clinic appointment.
The patient-centered SMAC-HF intervention was based on empirically-verified clinical 
management and pedagogical educational theory.[15] The pedagogy approach used with 
patients was based on the American College of Physicians’ Family Home Care Management 
Guide [16] and the Chronic Care Model (CCM) which emphasizes engaging patients in self-
management partnerships with multiple professionals.[17] Each group clinic visit included 
multidisciplinary health professionals: a nurse practitioner with extensive clinical experience 
in HF management, a mental health clinical nurse specialist, a social worker, and a dietician. 
At the beginning of each group clinic appointment, the patients’ weight, vital signs and HF 
symptoms were assessed, medications were reviewed, and depression screening conducted. 
Group appointment participants were shown how to complete daily self-monitoring/
checklist diaries with spaces to daily record weight, fluid/sodium intake, physical activity, 
emotions and moods, and HF symptoms.
Once the assessments were completed at each clinic appointment, the patients and the 
multidisciplinary health professionals sat at a round table to view and then discuss that 
clinics short HF DVD. This 5-part DVD series was produced under an NIH grant 
(SBIR-1R43AG1700701) and illustrated HF patients using the national ACCF/AHA 
guideline based HF self-management strategies.[18] A different DVD was shown at each 
group appointment with each DVD focusing on a different self-management topic.[19] 
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Control group participants who received standard care also received a copy of the HF DVD 
series. Thus, our short DVDs were used to standardize the educational information across 
groups, so that the primary difference between the study arms was exposure to group clinics.
At the end of each group clinic discussion, a one-page, HF self-management summary was 
completed. This form provided patients with a personal report of their trends in weight, 
blood pressure, heart rate, and depression scores. In addition, on this form, patients wrote 
questions they wanted to ask and discuss with their health care provider. Also the patient 
self-management summary indicated whether the patients were receiving a β blocker, an 
ACE inhibitor or ARB, or an aldosterone receptor antagonist. (For African American 
patients, the combination of hydralazine and a nitrate was considered equivalent to use of an 
ACE inhibitor or ARB.) Although each group visit was supervised by a nurse practitioner, 
this nurse practitioner did not directly alter the clinical treatment plan during the group visit, 
but rather worked with the patient to adhere to their prescribed regimen, to identify issues to 
address with their primary providers and for early referral of HF exacerbation symptoms to 
physicians.
Data Collection and Follow-up
Hospitalizations that occurred post-randomization were identified by querying hospital 
electronic medical records at the academic medical center. Copies of medical records were 
also requested for any hospitalizations that data collection uncovered or subjects reported 
occurring outside of the medical center. The control patients had follow-up data collection 
on the same time schedule as the intervention group participants. Nurses, blinded to group 
assignment, conducted telephone follow-up quarterly on all participants to ensure that all 
rehospitalizations were identified. An experienced physician, blinded to treatment arm 
assignment, reviewed these medical records using a priori determined adjudication rules, 
and classified each hospitalization as being “HF related” or “not related to HF.” Comparable 
methods were used to identify deaths and adjudicate the cause of death from obituary/death 
and medical records.
Measurements
The a priori primary outcome was time, in days, to cardiovascular-related death or the first 
heart failure-related hospitalization with the start time lagged to commence 8 weeks post-
randomization. Measures collected at baseline included: demographic variables (age and 
gender); measures of HF severity (including left-ventricular function and length of HF 
diagnosis); HF functional status as assessed by the Kansas City Cardiomyopathy 
Questionnaire score (KCCQ); [20] depressive symptoms as assessed by the Center for 
Epidemiological Studies Depression Scale (CES-D) [21] and patients’ current HF related 
medications. At the end of each group appointment, patients assigned to the intervention arm 
also rated each multidisciplinary group clinic and each DVD on a 5-point Likert scale 
ranging from 1 = not helpful to 5 = very helpful.
Statistical Analysis
Means (standard deviations) and frequencies (percentages) of baseline characteristics were 
calculated for the two treatment arms and compared using chi-square or Student’s t tests, as 
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appropriate. Survival analysis methods were used to analyze the primary outcome of time-
to-first HF related hospitalization or death, with censoring at 12 months post randomization 
which included the 8 weeks lag time for intervention completion. Kaplan-Meier survival 
estimates were calculated by treatment group, and a Cox proportional hazards regression 
model was used to determine whether treatment was significantly associated with the hazard 
(i.e., risk) of HF-related death or rehospitalization.
Tests for statistical assumptions were performed prior to performing the planned analyses. 
Thus, prior to conducting the Cox proportional hazard model, tests were conducted to verify 
the assumption that hypothesized treatment effects did not vary over time. However, these 
tests showed violation of the assumption that the hazards were independent of time. 
Specifically, the hazard functions crossed at month 7 (which is one month past the 6-month 
booster group appointment), indicating the effect of treatment was changing with time 
(Figure 2). When such a violation of statistical assumptions occurs, the Cox model does not 
provide a valid (unbiased) estimate of the treatment effect because these analyses require 
constant hazard ratios for group comparisons across the entire time period.[22] In this 
circumstance, a hazard ratio produced by such a model would be indicative of the ‘average’ 
effect of treatment over the entire period of interest and would not produce meaningful 
information about effects that change over time.
Consequently, a time-varying treatment effect was added to the Cox model to first test and 
then account for the changing effect of treatment over the period of interest. Based on the 
crossing hazards at 30 days after the final booster visit, an interaction term, zt, was added to 
the model, where zt was set to treatment group assignment if the event occurred prior to 30 
days post-intervention booster visit and set to zero otherwise. A test of this treatment-time 
interaction within the Cox model showed a significant change in the treatment effect 30 days 
after the post-intervention booster visit (p = 0.03), providing empiric evidence of the change 
in the hazard functions over time. In our primary analysis, we used hospital medical records 
to track outcomes on all patients, including those that did not complete telephone follow-
ups.
Since telephone follow-ups and obituaries were our primary means of identifying 
hospitalizations and deaths that might have occurred outside of the academic medical center, 
we performed another analysis in which subjects were censored on the date of last 
completed follow-up. We also compared recurrent or multiple HF related rehospitalizations 
between treatment arms using a counting process approach with the proportional means 
model using a robust sandwich covariance estimator. [23] Changes in medication usage over 
the course of the trial (baseline to 12 months post randomization) were compared between 
treatment arms using generalized estimating equations (GEE). All statistical analyses were 
completed using SAS® version 9.3.
Results
Of the 198 participants who enrolled in the study, 106 (53%) were randomized to the 
standard care control arm and 92 (47%) into the intervention arm. Of the 198 enrolled, 180 
(91%) completed 12-month follow up data; deaths and dropouts were similar across arms 
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(Figure 1). The randomization process was successful in creating comparable groups (Table 
1). The mean age of participants was 62.3 years (SD = 13.2 years); 76 (38%) were female; 
87 (44%) were African American; 105 (53%) were Caucasian; and 6 (3%) were other or 
more than one race. Participants reported having had a diagnosis of HF for an average 6.2 
years prior to study enrollment, (SD = 7.6 years; median=3.3 years); the mean Charlson 
Comorbidity Index score was 6.7 (SD = 2.8); the mean left ventricular ejection fraction 
(LVEF) was 30% (SD=16.1). There was no significant difference between intervention and 
control arm patients on LVEF (χ2 = 0.69, p=.41) with 94% in the control arm and 91% in the 
intervention arm having an LVEF < 40. In this sample, there were 14 patients EF >/= 40%. 
There was no difference in percentage of these patients with EF >/= 40% between the 
intervention and standard care participants (χ2= 0.69, p = 0.41). Between the intervention 
and standard care arms, there were no statistically significant differences on these measures 
at baseline (Table 1).
The intervention patients attended on average 4.6 of the 5 available intervention group clinic 
appointments. There were a total of 72 group clinic appointments held during the study and 
each group clinic appointment on average was rated by participants as 4.8 where 5 indicates 
very helpful. Participants rated the helpfulness of each DVD as 4.5 on a 5-point Likert scale. 
The intervention group reported watching the DVD series 2.7 times plus the times watched 
during each group clinic visit. The standard care control participants reported viewing the 
DVD series 3.6 times on average. There was no significant difference in the viewing time or 
exposure to the DVD series (χ2 = 3.27, p=0.71) between groups. No formal evaluation of 
DVD helpfulness was collected about individual DVDs from the control arm to avoid a 
potential co-intervention effect.
At baseline, the majority of patients were receiving treatment with recommended 
vasodilators (ACE inhibitor, ARB or hydralazine/nitrate combination) and β-blockers (Table 
2). Use of recommended vasodilators declined more in the standard care group (−15%) than 
in the intervention group (−5%) at 12 months (p = 0.04). There was a similar, although non-
significant higher decline in use of β-blockers in the standard care arm (−9%) than in the 
intervention arm (−1%) (p = 0.06).
Of the 198 subjects, 48 (24%) patients had one or more HF-related hospitalizations during 
the observation period. There were 2 deaths in each group. Overall a total of 52 (26%) 
patients experienced the primary outcome of HF-related hospitalizations or death), 22 (24%) 
in the intervention group and 30 (28%) receiving standard care. Based on examination of the 
treatment group hazard functions of time to first event, a time-varying treatment effect was 
identified. The hazard functions were approximately parallel up until month 7 (30 days after 
the 6 month booster group appointment) but crossed several times in the period thereafter, 
indicating the effect of treatment was changing with time (Figure 2). From the onset of the 
observation period, lagged 8 weeks to complete the intervention, up until month 7 (which is 
30 days after the 6 month booster clinic), the time-dependent Cox model identified a 
significantly longer event-free time associated with the intervention (p = 0.04). The hazard 
ratio for the a priori primary outcome (time to first HF related rehospitalization or death) 
during this period of follow-up was 0.45 (95% CI = 0.21, 0.98). This model also 
demonstrated that beyond month 7, there were no significant differences between treatment 
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groups (HR = 1.7, 95% CI = 0.7, 4.1). To determine the sensitivity of these results to our a 
priori choice of censoring, another Cox model analysis that censored participants following 
their last completed follow-up was performed and provided similar results (Figure 3). In a 
secondary analysis, which looked at the total HF-related hospitalizations, including repeat 
hospitalizations during the observation period; there were 28 total hospitalizations in the 
intervention group and 45 among those receiving standard care (HR = 0.68, 95% CI = 0.37, 
1.24).
Discussion
Nationally, approximately 25% of Medicare patients hospitalized with HF are readmitted 
within 30 days of discharge [3] and by 12 months approximately 40-60% of patients with 
HF are rehospitalized and 12 to 31% of patients die.[1] To address this concern, a large 
number of studies have been undertaken to improve discharge planning for patients with HF 
and to enhance post-discharge support and follow-up care. [24] Yet, case-management and 
disease management interventions, including follow-up programs, have not consistently 
demonstrated beneficial effects, improved outcomes, or reductions in health care costs.[25] 
The SMAC-HF program was the first controlled trial to examine group clinic appointments 
on rehospitalizations related to HF and the impact of DVD HF self-management videos 
alone. In this study, a benefit for the group clinic appointments was seen which lasted until 
month 7 or 30 days after the last ‘booster’ group clinic appointment, but this benefit was not 
maintained afterwards.
Although use of recommended HF medications was high in both arms, it is possible that 
some of the positive effect seen in this study could be due to the intervention group patients’ 
medication adherence. There was higher adherence to recommended vasodilators in the 
intervention group compared to the standard care group and a statistically insignificant 
increase in use of β blockers over time, also favoring the intervention group. The observed 
decline in use of HF related medications over time may have been due to non-adherence, 
adverse effects or to cost as numerous patients reported concerns about the costs of all their 
medications.[26] The social worker did assist each patient who voiced concern with 
applying for cost saving programs; however these may take months to fill. Notably there we 
no significant differences on patients reporting stopping medications because of cost 
between groups across the trial (χ2= 1.64, p = 0.22).
A variety of factors may have influenced the small observed differences between groups in 
medication adherence. One of the group clinic appointments was devoted primarily to 
medication management and adherence. These patients also received written information on 
optimal HF medication use as part of the individualized patient summaries provided at the 
end of each weekly group clinic appointment with instructions to share these summaries 
with their primary providers. They worked with the group clinic multidisciplinary team to 
list specific issues to monitor and discuss with their doctors, including questions related to 
their HF medications.
The SMAC-HF intervention was well-received by the participants as evidenced both by the 
positive evaluations from participants and by high rates of attendance to the group clinic 
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appointments. Other investigators have also observed positive responses from patients 
participating in group appointments. The success of group appointments for other disease 
conditions, however, has been difficult to replicate,[27] possibly due to lack of 
standardization of the information delivered or lack of a patient centered approach such as 
that used in SMAC-HF group discussions. Information variation was controlled in the 
SMAC-HF group clinics by the DVD series. The DVD audiovisual media may be 
particularly supportive to patients with neurologic or cognitive decline, different learning 
styles or lower health information literacy levels.[28] Use of the DVD during the group 
clinic appointment allowed standardization of the overall self-management theme but still 
allowed patients to discuss their own concerns with the oversight of multidisciplinary 
professionals input.
While improvements in outcomes were noted up until month 7 or 30 days after the last 
intervention booster group appointment, these positive outcomes were not sustained. This 
suggests that there may be a need for continuing the booster interventions after this time or a 
need to reinforce specific HF self-management skills such as using the pill organizer box for 
adhering to daily medications or clarifying low-sodium in food labels. However, other 
programs for HF have also shown decrements in the effectiveness of the tested intervention 
in the follow-up period. Also, it has been shown that in these NYHA Class III and IV HF 
patients, the overall poor prognosis may limit the impact of many treatments.
Limitations
One limitation of this study is that the overall HF related rehospitalization or death event 
rate in this study was much lower than anticipated.[29] In our total sample, 24% of patients 
had a rehospitalization for HF during 12 months of follow-up. The low rates of 
rehospitalization or death could also have reduced our ability to detect a persistence of the 
intervention effect beyond the last booster session. The relatively low event rate seen in this 
study could be related to the high levels of guideline concordant medications seen at 
baseline (Table 2); it also may reflect under-appreciated benefits of the DVD educational 
videos alone. The low rates of readmission also reduced our ability to detect a difference in 
all rehospitalizations where a 32% reduction in total HF hospitalizations was nevertheless 
not statistically significant. This reinforces the preliminary nature of the finding from this 
study. The length of time needed to set up the group clinic appointment enrollment also 
limited our ability to impact hospital readmissions that might happen early after the index 
hospitalization. Finally, this was a single-center study with unique features of an academic 
health center patient population; results might differ in settings where HF care was either 
more or less regimented. These characteristics limit the generalizability of the observed 
benefits. A future, multi-center study of a longer duration of patient support would help 
further clarify the potential benefits of the multidisciplinary group clinic approach.
Conclusion
Our findings suggest that group clinic appointments hold promise for reducing HF 
rehospitalizations, but these findings from this small, single-site study need to be confirmed 
in a larger, multi-site study. The group clinic appointments were highly rated by patients and 
the multidisciplinary professionals involved. Emerging reimbursement policies could 
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facilitate adoption of group appointments under the existing Current Procedural 
Terminology (CPT) codes and Medicare rules. The effect of the group clinic appointments, 
however, appears to be limited to the period of group clinic exposure. To reduce earlier 
rehospitalizations, future studies could consider initiating parts of the intervention prior to 
hospital discharge. Future studies of group appointments for HF might also consider 
additional telephone follow-up reinforcement, home visits, or additional booster sessions to 
sustain positive impact.
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Figure 1. 
Flowchart of SMAC-HF enrollment, randomization and follow-up to first HF-related 
rehospitalization or death.
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Figure 2. 
Kernel-smoothed hazard functions for the event HF rehospitalization or death. Zero was pre-
specified as the randomization date plus 8 weeks. The hazard functions represent the 
probability of HF rehospitalization or death at time t conditional on survival to that point. 
The group hazards cross at approximately 7 months post-randomization, with the rate of 
rehospitalization or death in the intervention group lower than that of the control group prior 
to 7 months.
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Figure 3. 
Kaplan-Meier survival estimates of time to first HF rehospitalization or death. Zero was pre-
specified as the randomization date plus 8 weeks. The dashed horizontal line at month 7 
(which is 30 days after the final booster group clinic appointment occurs) marks the month 
at which the difference in treatment group hazard functions cross, thus indicating the effect 
of treatment compared to standard care is different prior to and after this point. Up to month 
7 (all events with t > 30 days post-booster censored), the Cox model identified a 
significantly longer event-free time associated with the intervention (p = 0.04) for recipients 
of the intervention. The effect of the intervention did not extend into the later period of 
follow-up (p = 0.30).
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Table1
Patient baseline characteristics means & comparison between groups.
Overall
(n=198)
Intervention
(n=92)
Standard Care
(n=106)
p
Demographics
 Age, mean years (SD) 62.3 (13.2) 62.6 (14.1) 62.1 (12.5) 0.78
 Female gender, n (%) 76 (38) 40 (44) 36 (34) 0.17
 African American, n (%) 87 (44) 45 (49) 40 (38) 0.12
 Hispanic, n (%) 14 (7) 8 (9) 6 (6) 0.39
 Employed, n (%) 32 (16) 16 (17) 16 (15) 0.66
 Living alone, n (%) 136 (31) 22 (24) 38 (36) 0.06
Comorbidities
 Diabetes, n (%) 95 (48) 44 (48) 51 (48) 0.97
 Hypertension, n (%) 178 (90) 82 (89) 96 (91) 0.74
 Chronic lung disease, n (%) 81 (41) 40 (44) 41 (39) 0.49
 Current smoker, n (%) 53 (27) 30 (25) 23 (28) 0.60
 Charlson Comorbidity Index, mean (SD) 6.7 (2.8) 6.9 (3.0) 6.4 (2.7) 0.25
Cardiac function
 Ejection fraction, mean % (SD) 30 (16.1) 30 (15.6) 30 (16.6) 0.79
 EF>=40, n (%) 14 (7) 8 (4) 6 (3) 0.41
 Duration of HF, mean years (SD) 6.2 (7.6) 6.9 (8.9) 5.5 (6.2) 0.19
 Atrial fibrillation, index admission, n (%) 40 (20) 23 (25) 16(15) 0.09
Functional Status
 CES-D Depression score, mean (SD) 8.9 (6.6) 8.9 (6.0) 8.9 (7.0) 0.98
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Table 2
Changes in medication treatment use throughout the course of the trial among 184 subjects with a baseline 
LVEF < 40% (n = 184).
Standard Care Intervention
Baseline 12 months Change Baseline 12 months Change z (p) 
†
Medication n (%) n (%) n (%) n (%)
Recommended vasodilator 79 (79%) 54 (64%) −15% 72 (86%) 51 (81%) −5% 2.1 (0.04)
(ACE/ARB/Hydralazine & Nitrate)
β Blocker 97 (97%) 74 (88%) −9% 74 (88%) 55 (87%) −1% −1.9 (0.06)
Aldosterone antagonist 37 (37%) 37 (44%) 7% 38 (45%) 30 (48%) 2% 0.7 (0.5)
†
: Parameter estimates and p-values based on Generalized Estimating Equations
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